Ruscogenins: A Comprehensive Reference Article
1. Identity: Chemical Names, Botanical Sources, and Common Forms
1.1 Chemical Identity
Ruscogenin, chemically designated as (1-beta,3-beta,25R)-spirost-5-ene-1,3-diol, is a steroidal saponin compound having molecular formula C27H42O4 and molecular weight 430.6 g/mol. Its CAS registry number is 472–11–7, and it is classified as a natural spirostanol steroidal sapogenin. The term ruscogenins (plural) is commonly used in phytochemical and regulatory literature to denote a mixture of the two principal aglycones: ruscogenin and its structural isomer neoruscogenin. Studies dealing with the pharmacological properties of the Ruscus saponins have shown that the pharmacological action increases with the decrease of the number of sugar residues, and the most active compounds are neoruscogenin and ruscogenin, a mixture of which is the active ingredient of some commercial drugs.
The underground parts of Ruscus plants are a source of steroidal saponins that can be classified into two structural classes: the hexacyclic spirostanol saponins and the pentacyclic furostanol saponins. Ruscogenin itself is an aglycone (sapogenin) — the sugar-free core unit produced when these intact saponin glycosides are hydrolyzed.
1.2 Primary Botanical Sources
Ruscus aculeatus (family Asparagaceae), commonly known as Butcher's Broom, is the most well-known natural source of ruscogenin. It is a small evergreen shrub native to Europe, North Africa, and some parts of the Middle East. Other species within the Ruscus genus that contain ruscogenin include Ruscus colchicus, Ruscus hypoglossum, Ruscus hypophyllum, Ruscus hyrcanus, and Ruscus streptophyllus.
Ruscogenin was first isolated from Ruscus aculeatus L. and is also derived from the medicinal plant Ophiopogon japonicus (L.f) Ker-Gawl. (commonly known as Mondo Grass). The roots of O. japonicus are considered an ideal source for ruscogenin production since this herbaceous plant is easy to grow and has been widely cultivated in East Asia.
The primary active ingredients of butcher's broom are the steroidal saponins ruscogenin and neoruscogenin, present at up to 6% of the dried rhizome. The plant also contains other steroidal sapogenins and saponins (such as ruscin and ruscoside), fatty acids, sterols, flavonoids, coumarins, sparteine, tyramine, and glycolic acid.
1.3 Localization Within the Plant
Ruscogenin is primarily sourced from the roots and rhizomes of plants belonging to the genus Ruscus. Some of the traditional applications of the species seem related to particular compounds, since the highest concentration of ruscogenins is located in the rhizome. Accordingly, the official pharmacopoeial drug material is the dried rhizome (Rusci aculeati rhizoma), not the aerial parts.
1.4 Common Forms and Preparations
Ruscogenins enter commerce in several forms:
- Standardized dry rhizome extract: Standardized preparations with a recommended single dose of 350 mg taken three times daily are described in the European Union herbal monograph.
- Combination products: R. aculeatus has typically been used as part of a commercial combination product such as Cyclo 3 Fort. Various multi-ingredient commercial products contain between 30 and 150 mg of R. aculeatus per capsule in combination with hesperidin methyl chalcone and ascorbic acid, and the usual dosage is 2 to 3 capsules per day.
- Topical preparations: External preparations include ointments and suppositories intended for hemorrhoid treatment.
- Herbal teas and decoctions: Aqueous preparations such as infusions and decoctions from both the aerial parts and the roots and rhizomes of R. aculeatus have been prepared and studied.
- Isolated ruscogenin: The pure aglycone is available as a reference standard and research compound. Identification and quantification of ruscogenin and neoruscogenin — the main active principles — is performed by HPLC-MS/MS technique after hydrolysis with sulphuric acid in isopropanol.
2. Traditional and Historical Use
2.1 Mediterranean Antiquity and European Folk Medicine
Ruscus aculeatus, a perennial shrub native to the Mediterranean and Black Sea regions and naturalized in parts of Europe and North America, has been traditionally employed in folk medicine for the treatment of venous insufficiency, hemorrhoids, edema, and various dermatological and urinary ailments.
In ancient Greece, butcher's broom was used as a laxative and to treat kidney stones. In Europe, a wine decoction of the root was used as a diuretic to treat urinary obstructions, kidney stones, and gravel.
According to reported folk knowledge, the aerial parts are mainly used as diuretics, and the underground organs are used for the treatment of disorders of the urinary system and as a laxative. The underground parts (roots and rhizomes) have also been used empirically to alleviate symptoms of venous insufficiency, edema, urinary system disorders, premenstrual syndrome, and hemorrhoids.
In Europe, Ruscus species were traditionally harvested for their flat and stiff branches to make small brooms that were used for clearing off and cleaning butchering blocks — hence the common name "Butcher's Broom."
2.2 Regulatory Recognition of Traditional Use in Europe
Ruscus aculeatus has been used for over a decade as an herbal substance or herbal preparation notably in France and Germany, since 1986 and 1978, respectively. Available monographs describe its use as "traditionally used in subjective symptoms of chronic insufficiency such as sensation of heavy legs" and as "supportive therapy for symptoms of chronic venous insufficiency," as well as supportive therapy for complaints of hemorrhoids such as itching and burning.
The German Commission E monograph approved it for complaints of chronic venous insufficiency, pain and heaviness in the legs, nocturnal calf cramps, itching and swelling, and also for itching and burning in hemorrhoids. The ESCOP monograph similarly recognizes its supportive use for chronic venous insufficiency with symptoms of aching, tired and heavy legs, tingling, and swelling of the legs, as well as for burning and pain in hemorrhoids.
2.3 Traditional Use in East Asian Medicine
Ophiopogonis Radix (Maidong in Chinese), the root of Ophiopogon japonicus, is widely used in local medicines of China, Japan, and some south-eastern Asian countries. According to the Traditional Chinese Medicine (TCM) principle, Ophiopogonis Radix nourishes the yin, promotes body fluid production, moistens the lung, eases the mind, and clears away heart fire. Ruscogenin is one of the key steroidal sapogenins extracted from this plant. Ruscogenin is also a major steroidal sapogenin of the traditional Chinese herb Radix Ophiopogon japonicus, which has been clinically used to treat acute and chronic inflammatory and cardiovascular diseases.
In the 1950s, scientific research proved the presence of valuable saponin compounds in butcher's broom, which are responsible for the healing properties of the raw material.
3. Key Constituents and Active Compounds
3.1 The Ruscogenin Complex
The therapeutic applications of R. aculeatus are attributed primarily to the presence of steroidal saponins such as ruscogenin and neoruscogenin, as well as flavonoids and other bioactive compounds. The specific saponins found in butcher's broom are ruscogenins, ruscogenen and neoruscogenin, named for the genus Ruscus.
The main active ingredients found in R. aculeatus are steroidal saponins (ruscogenin and neoruscogenin), which are responsible for its pharmacological effects. Other constituents that have been isolated include sterols, triterpenes, flavonoids, coumarins, sparteine, tyramine, and glycolic acid.
3.2 Structural Classification of Saponins
Phytochemical examination of the underground parts of R. aculeatus has led to the isolation of six new spirostanol saponins and five new furostanol saponins, whose structures were assigned on the basis of spectroscopic analysis including two-dimensional NMR techniques, and hydrolysis. The intact glycosides in the plant — such as ruscoside and desglucoruscoside — yield the aglycones ruscogenin and neoruscogenin upon hydrolysis. Like all spirostane prosapogenins, these take origin from furostanol saponins carrying a glucose residue at C-26. Two furostanol saponins containing a double bond in the 25–27 position have been described in R. aculeatus: ruscoside and desglucoruscoside.
3.3 Secondary Phytochemical Constituents
Newer research has also uncovered that there are polyphenols present in butcher's broom which may also be physiologically active, possibly as antioxidants. Nine phenolic compounds have been detected in aqueous and hydroethanolic extracts of R. aculeatus, with apigenin-C-hexoside-C-pentoside being the major compound in aqueous extracts, and quercetin-O-deoxyhexoside-hexoside being prominent in hydroethanolic extracts.
4. Established Mechanisms of Action
4.1 Alpha-Adrenergic Venoconstriction
Ruscus aculeatus is an alpha-adrenergic agonist that causes venous constriction by directly activating postjunctional alpha1- and alpha2-receptors, in turn stimulating the release of noradrenaline. This mechanism explains the venotonic properties attributed to ruscogenins — the reduction of venous capacity and pooling of blood in the lower extremities.
4.2 Inhibition of NF-κB Signaling and ICAM-1 Expression
The best-characterized molecular mechanism of ruscogenin is its effect on the NF-κB inflammatory pathway. Ruscogenin, also a major steroidal sapogenin of the traditional Chinese herb Radix Ophiopogon japonicus, has been found to exert significant anti-inflammatory and anti-thrombotic activities. Earlier studies demonstrated that ruscogenin remarkably inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV304) injured by tumor necrosis factor-α (TNF-α) in a concentration-dependent manner.
In vivo studies showed that ruscogenin significantly suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner. It also inhibited TNF-α-induced overexpression of ICAM-1 both at the mRNA and protein levels and suppressed NF-κB activation considerably by decreasing NF-κB p65 translocation and DNA binding activity. These findings provide insights into the possible molecular mechanism of ruscogenin for the inhibition of endothelial responses to cytokines during inflammatory and vascular disorders.
Further investigations showed that ruscogenin significantly suppressed p65 phosphorylation, IκB-alpha phosphorylation and degradation, and inhibited IKKα and IKKβ activation induced by TNF-α. It exerted weak effects on TNF-α-induced phosphorylations of p38, JNK, ERK1/2, and Akt. Overall, downregulation of ICAM-1 expression by ruscogenin in HUVECs appeared to be mediated primarily by NF-κB, but not by MAPK and Akt signaling pathways.
4.3 Reduction of Capillary Permeability and Anti-Elastase Activity
Ruscogenin has been reported to exert robust anti-inflammatory activities, acting as an anti-elastase, decreasing capillary permeability, and widely used to treat chronic venous insufficiency and vasculitis. These effects on capillary wall integrity underpin the anti-edema properties observed in clinical settings.
4.4 Suppression of Tissue Factor and iNOS in Acute Lung Injury
The endothelial-protective effects and anti-inflammatory mechanism of ruscogenin are associated with suppression of ICAM-1 expression through inhibition of the NF-κB signaling pathway. A study also showed that ruscogenin significantly attenuates LPS-induced acute lung injury by inhibiting the expression of tissue factor (TF) and inducible nitric oxide synthase (iNOS) and by inhibiting NF-κB p65 activation, indicating potential as a therapeutic agent for acute lung injury or sepsis.
4.5 NLRP3 Inflammasome Inhibition
Ruscogenin has been shown to inhibit NLRP3 inflammasome activation and canonical pyroptosis, at least in part through the suppression of the TLR4/NF-κB signaling pathway. These findings may provide a foundation for exploring the therapeutic potential of ruscogenin in the treatment of inflammatory bowel disease.
4.6 RORα Nuclear Receptor Agonism
Neoruscogenin — the co-aglycone present alongside ruscogenin in standardized preparations — has been identified as a potent and high-affinity agonist of the nuclear receptor RORα (NR1F1). RORα is involved in the regulation of circadian rhythm, lipid metabolism, and immune function, and this interaction may contribute to some of the pleiotropic effects attributed to ruscogenins.
4.7 Anti-Cancer Mechanisms (Preclinical)
In preclinical studies, ruscogenin markedly inhibited the viabilities of pancreatic cancer cells both in vitro and in vivo. Ruscogenin markedly inhibited the viabilities of pancreatic cancer cells both in vitro and in vivo, and the in vitro studies further revealed that ruscogenin induced pancreatic cancer cell death through abnormal increases in intracellular ferrous iron and increased levels of reactive oxygen species (ROS) — a form of cell death known as ferroptosis. Separately, ruscogenin was shown to significantly decrease the expression of MMP2, MMP9, VEGF, uPA, and HIF-1α to suppress hepatocellular carcinoma metastasis.
5. Scientific Evidence by Area of Use
5.1 Chronic Venous Insufficiency (CVI)
Clinical Evidence (Combination Preparations): Most clinical research on ruscogenins has been conducted with the proprietary preparation Cyclo 3 Fort, which combines Ruscus aculeatus root extract (150 mg per capsule) with hesperidin methyl chalcone (HMC) (150 mg) and ascorbic acid (100 mg). Despite its widespread use, studies regarding R. aculeatus remain limited, and many investigations have focused on complex formulations such as Cyclo 3 Fort, which also contains hesperidin methylchalcone and ascorbic acid, making it difficult to attribute the observed effects solely to R. aculeatus.
A meta-analysis using data from all clinical trials of Cyclo 3 Fort was carried out to estimate the overall effect on the symptoms and severity of chronic venous insufficiency. The meta-analysis (Boyle, Diehm & Robertson, 2003) included 20 placebo-controlled, randomized, double-blind studies and 5 randomized studies against a comparator drug. Compared to placebo, the authors demonstrated significant reductions in the severity of pain, cramps, heaviness, paresthesia and venous capacity with Cyclo 3 Fort, in addition to reductions in edema severity.
A subsequent systematic review and meta-analysis of randomized double-blind placebo-controlled trials (Kakkos & Allaert, 2017) focusing on 10 RCTs found that Ruscus extract + HMC + AA (Cyclo 3 Fort), compared with placebo, significantly reduced the sensation of swelling (RR 0.53; P < .0001, NNT = 4), and decreased ankle circumference and leg/foot volume.
In one open-label observational study, treatment consisted of two capsules per day of Ruscus aculeatus 150 mg/HMC 150 mg/ascorbic acid 100 mg during 8 weeks. A total of 124 patients were studied, 109 female (89.28%), with a mean age of 52.5. Initial intense reports were 79% pain, 85% heaviness, 74% cramps, and 82% edema, decreasing to 20%, 12%, 8% and 14% respectively within two weeks, with symptomatology being absent at the end of treatment.
Evidence Strength: A daily dose equivalent to an amount of 7 to 11 mg of total ruscogenins has been recommended by available monographs; however, the level of evidence of Ruscus extract efficacy in relieving symptoms of chronic venous insufficiency given by individual studies is low. Studies mentioned in the ESCOP monograph present serious limitations. The EMA has therefore classified its use under "traditional use" rather than "well-established use" for most preparations, reflecting the methodological limitations of the available clinical trial base and the confounding presence of other active ingredients in combination products.
5.2 Hemorrhoids
The rhizome and root have been employed in folk medicine for the treatment of hemorrhoids, supported by the vasoconstricting and anti-inflammatory properties of ruscogenins. The HMPC monograph supports its traditional use for complaints associated with hemorrhoids such as burning and itching, the ESCOP monograph includes burning and pain in hemorrhoids, and the German Commission E approved its use for itching and burning in hemorrhoids. Topical preparations including suppositories are described for this indication. Dedicated high-quality clinical trials focused specifically on the isolated ruscogenin fraction for hemorrhoids are lacking; the regulatory status remains "traditional use" in the EU.
5.3 Orthostatic Hypotension and Venous Pooling
Unlike most drug therapies used to treat orthostatic hypotension (OH), Ruscus aculeatus does not cause supine hypertension. It also appears to alleviate the worsening effects of OH in environmentally hot conditions. Ruscus aculeatus, a phytotherapeutic agent containing ruscogenins and flavonoids, may prove useful for the treatment of OH if denervation is not so advanced that it has compromised receptor activity at the venous wall. This area of use is supported by the known alpha-adrenergic mechanism; published evidence consists primarily of case reports and mechanistic pharmacodynamic studies rather than large controlled trials.
5.4 Anti-Inflammatory Applications
Ruscogenin exhibits marked anti-inflammatory activity, evidenced by its ability to reduce vascular permeability and suppress leukocyte adhesion. It effectively inhibits TNF-α-driven NF-κB p65 activation and ICAM-1 overexpression, demonstrating a strong regulatory effect on inflammatory signaling pathways. Ruscogenin significantly decreases edema formation in vivo, producing around a 50% reduction in paw swelling at therapeutic doses. Current evidence is largely derived from in vitro and animal models; direct human clinical trials specifically assessing ruscogenin's anti-inflammatory effects as an isolated compound are not yet established in the reviewed literature.
5.5 Neurological Protection (Preclinical)
In a mouse model of experimental stroke using middle cerebral artery occlusion (MCAO), NF-κB DNA binding activity, and the expression of NF-κB target genes including ICAM-1, iNOS, COX-2, TNF-α and IL-1β, were suppressed by ruscogenin pretreatment after 1 hour of MCAO and 24 hours of reperfusion. The results indicated that ruscogenin protected the brain against ischemic damage, an effect proposed to occur through downregulation of NF-κB-mediated inflammatory responses. This evidence is preclinical (animal model) only, with no human clinical trials in this area identified in the available literature.
5.6 Pulmonary Hypertension (Preclinical)
A study examined the effect of ruscogenin on pulmonary arterial hypertension (PAH) using isolated pulmonary vascular smooth muscle cells (PVSMCs) from rat pulmonary artery, cultured in vitro and treated with platelet-derived growth factor (PDGF). The protective effects of ruscogenin appeared from the dose of 0.1 mg/kg and became more apparent at the dose of 0.4 mg/kg; a further increase in the dose to 0.7 mg/kg did not increase the effect. This work is preclinical; no human trials in pulmonary hypertension have been identified.
5.7 Diabetic Nephropathy (Preclinical)
Ruscogenin has been shown to exert robust anti-inflammatory and anti-fibrotic activities, decrease capillary permeability, and act as an anti-elastase. It is a major steroidal sapogenin of the traditional Chinese herb Radix Ophiopogon japonicus, clinically used to treat acute and chronic inflammatory and cardiovascular diseases. The anti-inflammatory mechanism has been linked to suppression of ICAM-1 expression in endothelial cells mainly through the inhibition of the NF-κB signaling pathway. Studies in streptozotocin-induced diabetic rats have investigated its potential to reduce renal inflammatory and fibrotic damage. This evidence is animal-based only.
5.8 Anti-Osteoporotic Effects (Preclinical)
Research by Chakuleska et al. revealed that ruscogenin shows estrogen-like, antioxidant, and anti-osteoporosis effects in ovariectomy-induced osteoporosis in rats. This finding is from an animal model, and no human studies on osteoporosis have been identified in the reviewed literature.
5.9 Anticancer Activity (Preclinical Cell and Animal Studies Only)
Ruscogenin also shows anti-cancer properties, leading to apoptosis and hindering metastasis, particularly in pancreatic and hepatocellular carcinoma. The cell death mechanism involved in pancreatic cancer cells appears to be ferroptosis: ruscogenin markedly inhibited the viabilities of pancreatic cancer cells both in vitro and in vivo, and induced pancreatic cancer cell death accompanied by abnormal increases in intracellular ferrous iron and increased levels of ROS. In hepatocellular carcinoma, the hypotoxicity of ruscogenin was indicated while it showed obvious interruption of cancer cell migration and invasion, and inhibition of metastatic foci in pulmonary tissue. All anticancer evidence is preclinical (cell lines and rodent models); no human oncology trials have been identified.
5.10 Inflammatory Bowel Disease (Preclinical)
Ruscogenin, a prominent steroidal sapogenin present in Radix Ophiopogon japonicus, has shown protective effects in attenuating inflammatory responses associated with inflammatory diseases. In a dextran sulfate sodium (DSS)-induced C57BL/6 mouse colitis model, ruscogenin treatment attenuated the symptoms of ulcerative colitis, reduced the release of inflammatory cytokines and the expression of pyroptosis-associated proteins, and restored the integrity of the intestinal epithelial barrier in colon tissue in mice. This is preclinical evidence only.
6. Body Systems and Health Areas Associated with Ruscogenins
- Cardiovascular / Venous System: Venotonic and vasoprotective effects; chronic venous insufficiency; varicose veins; reduction of venous pooling and edema. The most important active constituents — ruscogenin and neoruscogenin — are widely studied for their effects on blood vessel tone and vascular function.
- Anorectal System: Traditional and officially recognized use for hemorrhoids.
- Autonomic / Circulatory Regulation: Alpha-adrenergic agonism relevant to orthostatic hypotension.
- Pulmonary System: Preclinical evidence in pulmonary arterial hypertension and acute lung injury models.
- Neurological System: Preclinical neuroprotection in cerebral ischemia models.
- Renal System: Preclinical anti-inflammatory and anti-fibrotic effects in diabetic nephropathy models.
- Skeletal / Bone System: Preclinical estrogen-like and anti-osteoporotic effects.
- Oncology: Preclinical ferroptosis-inducing and anti-metastatic activity in liver and pancreatic cancer cells.
- Gastrointestinal System: Preclinical evidence in ulcerative colitis via NLRP3 inflammasome inhibition; historical use as a laxative.
- Urinary System: Historical / traditional use as a diuretic for urinary complaints.
- Skin: Ruscogenin has been demonstrated to possess skin-lightening properties as a therapeutic agent.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are reported in the cited sources and regulatory documents; they are descriptive of what has been studied or authorized, not prescriptive recommendations.
- EMA Herbal Monograph (oral dry extract): Single dose: 350 mg, three times daily.
- Daily ruscogenin target (EMA HMPC comments): A daily dose equivalent to an amount of 7 to 11 mg of total ruscogenins is referenced in EMA assessment documentation.
- Cyclo 3 Fort (combination product): Cyclo 3 Fort consists of root extract of Ruscus aculeatus (150 mg per capsule), hesperidin methyl chalcone (150 mg) and ascorbic acid (100 mg). Various multi-ingredient commercial products contain between 30 and 150 mg of R. aculeatus per capsule, and the usual dosage is 2 to 3 capsules per day.
- Clinical observational trial (CVI, 8 weeks): Treatment consisted of two capsules per day of Ruscus aculeatus 150 mg / HMC 150 mg / ascorbic acid 100 mg during 8 weeks.
- Preclinical dose (pulmonary hypertension, rat): Protective effects of ruscogenin appeared from the dose of 0.1 mg/kg and became more apparent at the dose of 0.4 mg/kg; a further increase to 0.7 mg/kg did not increase the effect.
- In vitro anti-inflammatory (ICAM-1/NF-κB, ECV304 cells): Cells were pretreated with ruscogenin (0.01, 0.1, and 1 μM) and dexamethasone (1 μM) for 1 hour and then stimulated with TNF-α (10 ng/ml) for 4 hours.
8. Safety Considerations and Drug Interactions
8.1 General Tolerability
Butcher's broom contains substances with alpha-adrenergic stimulating activity. In a clinical trial in patients with chronic phlebopathy of the lower limbs (N=40), no adverse events were attributable to R. aculeatus.
8.2 Cardiovascular Safety Caution
Patients with hypertension may experience an increase in blood pressure with ruscogenin-containing preparations due to the alpha-adrenergic venoconstricting mechanism. This is a pharmacologically plausible and clinically relevant consideration in hypertensive individuals.
8.3 Interactions with Alpha-Adrenergic Agents
No drug interactions are well documented. Theoretically, interactions with alpha-adrenergic–stimulating agents are possible, given that butcher's broom contains substances with alpha-adrenergic stimulating activity. Conversely, preclinical information about butcher's broom's pharmacodynamics also suggests the possibility of interference with the efficacy of alpha-blockers.
8.4 Pregnancy and Lactation
Information regarding safety and efficacy in pregnancy and lactation is lacking. Preparations have been studied in pregnancy-related varicosities; however, safety has not been established.
8.5 Known Hypersensitivity
Contraindication is noted for hypersensitivity to the active substance(s).
8.6 Poisoning Reports
The Milan Poison Control Centre handled 107 R. aculeatus poisoning cases in the period 1995–2007, with subsequently 4 acute poisoning cases recorded for 2010–2[012]. These cases are associated with the plant itself, most likely resulting from ingestion of the red berries, which are distinct from the prepared rhizome extract.
8.7 Limitations of Safety Data
The available data support the plant's traditional use, yet further well-designed experimental and clinical studies are needed to clarify its mechanisms of action, confirm its therapeutic potential, and ensure safety and standardization in medicinal preparations.
References
Go back